Search Results for: covid-19
Articles
July 30, 2024
IMUNON Announces 11.1 Month Increase in Overall Survival in Patients With Newly Diagnosed, Advanced Ovarian Cancer Treated With IMNN-001
IMUNON, Inc. recently announced positive topline results from the Phase 2 OVATION 2 Study with IMNN-001 in patients with advanced...
July 11, 2024
Rentschler Biopharma Announces New State-of-the-Art Production Line in Massachusetts is Fully Operational
Rentschler Biopharma SE recently announced the company’s new state-of-the-art production line, formerly known as the Rentschler Biopharma Manufacturing Center (RBMC),...
July 3, 2024
CureVac Initiates Strategic Restructuring to Align Resources With Focus on High-Value mRNA Pipeline Opportunities
CureVac N.V. recently announced a significant strategic restructuring to focus its resources on high-value mRNA projects in oncology and other...
June 20, 2024
API & the University of Alberta Break Ground on Canada’s Largest Manufacturing Facility for Critical Medicines
Construction is set to begin on a crucial pharmaceutical manufacturing facility in the Edmonton Research Park that will provide Canadians...
June 18, 2024
Truveta Announces Support for Regulatory Submissions to the FDA & Global Regulatory Authorities
Truveta recently announced regulatory and audit capabilities to support its customers for real-world evidence (RWE) submissions to the US FDA...
June 6, 2024
Atriva Therapeutics Secures US Patent for First-in-Class Broad Spectrum Therapy for Severe RNA Virus Infections Including Bird Flu
Atriva Therapeutics recently announced it has been granted a US patent for its MEK inhibitor zapnometinib (ATR-002). The patent includes...
June 5, 2024
First Participants Vaccinated in IMUNON’s Phase 1 Clinical Trial
IMUNON, Inc. recently announced the first participants have been treated in the IMNN-101 Phase 1 clinical trial. This proof-of-concept study...
June 4, 2024
ExeVir Bio Announces Exceptional Virus Neutralization Potency of its Variant-Proof Antibody Against the SARS-CoV-2 Variant JN.1
ExeVir Bio recently announced new data demonstrating its antibodies are exceptionally potent in neutralizing the SARS-CoV-2 variant JN.1, the parental...
June 3, 2024
CONTAINER PLATFORMS - Ready-to-Use Containers: Real Benefits, Important Challenges & Evolving Value
Gregor Deutschle and Gabriele Maier examine key benefits, dynamics driving the adoption of RTU container platforms, and several important areas of continuing evolution in the RTU market.
May 29, 2024
BioNTech & CEPI Expand Partnership to Strengthen Africa’s mRNA Vaccine Ecosystem
BioNTech SE and the Coalition for Epidemic Preparedness Innovations (CEPI) are expanding their strategic partnership to contribute to building a sustainable...
